Surgical pathologic factors in patients with early-stage cervical carcinoma treated with radical hysterectomy and pelvic lymph node dissection: association with administration of adjuvant radiotherapy and effect on survival

Purpose of investigation: To identify surgical pathologic factors that best correlate with administration of adjuvant radiotherapy and best predict survival in early-stage cervical carcinoma treated with radical hysterectomy and pelvic lymph node dissection (RHND).

Methods: Data from the files of 126 patients with cervical carcinoma treated by RHND at the Soroka Medical Center from 1962 through 2005 were analyzed.

Results: Fifty-four percent of the patients received postoperative adjuvant radiotherapy. In a univariate analysis, each of the following factors: positive pelvic lymph nodes, lower uterine segment involvement, lymph vascular space involvement, penetration > or = 50% of the cervical wall, grade 2+3, parametrial and/or paracervical involvement, vaginal margin involvement, non-squamous histologic type, tumor size > or = 3 cm and Stage IB2 + IIA was significantly associated with administration of radiotherapy. In a multivariate analysis, positiviy of pelvic lymph nodes was persistently the most significant factor associated with administration of radiotherapy. The 5-year survival rate was 82.6% overall. In a univariate analysis, a significant worsening in survival was demonstrated with positivity of pelvic lymph nodes and positivity of lymph vascular space involvement. In a "better fit" model of multivariate analysis, pelvic lymph node status was the strongest and the only significant predictor of survival.

Conclusions: In patients with early-stage cervical carcinoma treated with radical hysterectomy and pelvic lymph node dissection, pelvic lymph node status is the strongest factor affecting administration of adjuvant radiotherapy and the most significant predictor of survival.

Cervical carcinoma; Prognostic factors; Adjuvant radiotherapy; Survival

[1] Landoni F., Maneo A., Colombo A., Placa F., Milani R., Perego P et al.: "Randomized study of radical surgery versus radiotherapy for Stage lb-lla cervical cancer". Lancet, 1997, 350, 535.

[2] Eifel P.J., Berek J.S., Thigpen J.T.: "Cancer of the cervix, vagina, and vulva". In: DeVita Y.T., Hellman S., Rosenberg S.A. (eds.) "Cancer: Principles and Practice of Oncology". 6th edition, Philadelphia, JB Lippincott, Williams and Wilkins, 2001, 1526.

[3] Petercit D.G., Eifel P.J., Thomas G.M.: "Cervical cancer". In: Gunderson L.L., Tepper J.E. (eds.) "Clinical Radiation Oncology" Philadelphia, Churchill Livingstone, 2000, 886.

[4] Shinohara S., Ochi T., Miyazaki T., Fujii T., Kawamura M., Mochizuki T., Ito M.: "Histopathological prognostic factors in patients with cervical cancer treated with radical hysterectomy and postoperative radiotherapy". Int. J. Clin. Oneal., 2004, 9, 503.

[5] Kim J.H., Kim H.J., Hong S., Wu H-G., Ha S.W.: "Post-hysterectomy radiotherapy in FIGO Stage IB-ITB uterine cervical carcinoma". Gynecol. Oneal., 2005, 96, 407.

[6] Van de Putte G., Lie A.K., Yach W., Baekelandt M., Kristensen G.B.: "Risk grouping in Stage IB squamous cell cervical carcinorna". Gynecol. Oneal., 2005, 99, 106.

[7] Monk B.J., Cha D-S., Walker J.L., Burger R.A., Ramsingham N.S., Manetta A. et al.: "Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of Stage IB and IIA cervical carcinoma". Gynecol. Oneal., 1994, 54, 4.

[8] Smiley L.M., Burke T.W., Silva E.G., Morris M., Gershenson D.M., Wharton J.T.: "Prognostic factors in Stage IB squamous cervical cancer patients with low risk for recurrence". Obstet. Gynecol., 1991, 77, 271.

[9] Piver M.S., Rutledge F.N., Smith P.J.: "Five classes of extended hysterectomy for women with cervical cancer". Obstet. Gynecol., 1974, 44, 265.

[10] Shepherd J.H.: "Revised FIGO staging for gynaecological cancer" Br. J. Obstet. Gynaecol., 1989, 96, 889.

[11] Swinscow T.D.Y.: "Statistics at Square One". Tavistock Square, London, British Medical Association, 1983.

[12] Morrison D.F.: "Multivariate statistical methods". New York, McGraw-Hill, 1990.

[13] Kaplan E.L., Meier P.: "Non-parametric estimation from mcomplete observations". J. Am. Stat. Assoc., 1958, 53, 457.

[14] Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.Y. et al.: "Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples". Br. J. Cancer, 1977, 35, 1.

[15] Cox D.R.: "Regression models and life tables". J. Roy. Stat. Soc., 1972, 34B, 187.

[16] Morris M.: "Early cervical carcinoma: Are two treatments better than one?" (editorial). Gynecol. Oncol., 1994, 54, 1.

[17] Bremer G.L., van der Putten H.W., Dunselman G.A., de Haan J. "Early stage cervical cancer: aborted versus completed radical hysterectomy". Eur. J. Obstet. Gynecol. Ruprod. Biol., 1992, 47, 147.

[18] Michel G., Morice P., Castaigne D.. Leblanc M., Rey A., Duvillard P.: "Lymphatic spread in stage Tb and TT cervical carcinoma: anatomy and surgical implications". Obstet. Gynecol., 1998, 91, 360.

[19] Lagasse L.D., Smith M.L., Moore J.G., Morton D.G., Jacobs M., Johnson G.H., Watring W.G.: "The effect of radiation therapy on pelvic lymph node involvement in Stage I carcinoma of the cervix". Am. J. Obstet. Gynecol., 1974, 119, 328.

[20] F letcher G.H.: "Lucy Wortham James Lecture. Subclinical disease". Cancer, 1984, 53, 1274.

[21] Girardi F., Pickel H., Winter R.: "Pelvic and parametrial lymph nodes in the quality control of the surgical treatment of cervical cancer". Gynecol. Oneal., 1993, 50, 330.

[22] Kinney WK., Hodge D.O., Egorshin E.V., Ballard DJ., Podratz K.C.: "Surgical treatment of patients with Stages 1B and TIA carcinoma of the cervix and palpably positive pelvic lymph nodes".

[23] Lin H.H., Cheng W.F., Chan K.W., Chang D.Y., Chen C.K., Huang S.C.: "Risk factors for recurrence in patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation". Obstet. Gynecol., 1996, 88, 274.

[24] Bloss J.D., Berman M.L., Mukhererjee J., Manetta A., Emma D., Ramsanghani N.S., DiSaia P.J.: "Bulky Stage 1B cervical carcinoma managed by primary radical hysterectomy followed by tailored radiotherapy". Gynecol. Oncol., 1992, 47, 21.

[25] Burghardt E.: "Cervical cancer". In: Burghardt E., Webb M.J., Monaghan J.M., Kindermann G. (eds.). "Surgical Gynecologic Oncology". New York, Georg Thieme Verlag Stuttgart, Thieme Medical Publishers Inc., 1993, 185.

[26] F erraris G., Lanza A., Re A., Raspollini M., Proserpio D., Bellmo R.: "The significance of lymph node status at pelvic, common iliac and para-aortic levels". Baillieres Clin. Obstet. Gynaecol., 1988, 2, 913.

[27] Inoue T., Morita K.: "The prognostic significance of number of positive nodes in cervical carcinoma Stages IB, TIA, and IIB". Cancer, 1990, 65, 1923.

[28] Sevin B-U., Nadji M., Lampe B., Lu Y., Hilsenbeck S., Koechh O.R., Averette H.E.: "Prognostic factors of early stage cervical cancer treated by radical hysterectomy". Cancer, 1995, 76, 1978.

[29] Piura B., Dgani R., Yanai-Tnbar I., Cohen Y., Glezerman M.: "Adenocarcinoma of the uterine cervix: a study of 37 cases". J. Surg Oncol., 1996, 61, 249.

[30] Hatch K.D.: "Cervical cancer". In Berek J.S., Hacker N.F . (eds.). "Practical Gynecologic Oncology". Baltimore, Williams & Wilkins, 1989, 258.

[31] Nahhas W.A., Sharkey F.E., W hitney C.W., Husseinzadeh N., Chung C.K., Mortel R.: "The prognostic significance of vascular channel involvement and deep stromal penetration in early cervical carcinoma". Am. J. Clin. Oneal., 1983, 6, 259.

[32] Sevin B-U., Lu Y., Bloch D.A., Nadji M., Koechli O.R., Averette H.E.: "Surgically defined prognostic parameters in patients with early cervical carcinoma. A multivariate survival tree analysis". Cancer, 1996, 78, 1438.

[33] Kamura T., Tsukamoto N., Tsuruchi N., Saito T., Matsuyama T., Akazawa K., Nakano H.: "Multivariate analysis of the histopathologic prognostic factors of cervical cancer in patients undergoing radical hysterectomy". Cancer, 1992, 69, 181.